Rhino-Orbital-Cerebral mucormycosis

Current Infectious Disease Reports

Volumn 14, Issue 4, 2012, Pages 423-434

  Gamaletsou, Maria N ^a   Sipsas, Nikolaos V ^a   Roilides, Emmanuel ^b   Walsh, Thomas J ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Cornell University ^*  (United States)

Author keywords

Cerebral mucormycosis; Orbital mucormycosis; Rhinocerebral mucormycosis; Sinusitis

Indexed keywords

AMPHOTERICIN B; DEFERASIROX; ECHINOCANDIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POSACONAZOLE;

ARTICLE; BRAIN INFECTION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DEBRIDEMENT; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; HUMAN; HYPERBARIC OXYGEN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION CONTROL; INFECTION RISK; MACROPHAGE; MICROSCOPY; MONOCYTE; MONOTHERAPY; MUCORALES; MUCORMYCOSIS; NEUTROPHIL; NONHUMAN; ORBIT INFECTION; OUTCOME ASSESSMENT; PATHOGENESIS; RHINO ORBITAL CEREBRAL MUCORMYCOSIS; RISK ASSESSMENT; SALVAGE THERAPY; SINUSITIS; SPORANGIOSPORE; TREND STUDY;

EID: 84865629000     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0272-6     Document Type: Article

References (154)

1. Walsh TJ, Bloom BE, Kontoyiannis DP. Meeting the challenges of an emerging pathogen: The Henry Schueler 41&9 Foundation International Forum on Mucormycosis. Clin Infect Dis. 2012;54: S1-4.
2. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Mucormycosis (mucormycosis): Emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17:517-25. (Pubitemid 39627512)
3. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis. 2011;17:1855-64. Important data describing temporal patterns of increasing mucormycosis in transplant patients.
4. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of mucormycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41:634-53. (Pubitemid 41170352)
5. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin Infect Dis. 2012;54:S8-S15. Valuable review of current understanding of nomenclature and molecular taxonomy of mucorales.
6. Lanternier F, Dannaoui E, Morizot G, French Mycosis Study Group, et al. A global analysis of mucormycosis in France: The RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54:S35-43.
7. Larone D. Identification of medically important fungi. ASM Press; 2012. New edition of important diagnostic text. 8.
8. Petraitis V, Petraitiene R, Antachopoulos C, et al. Increased virulence of Cunninghamella bertholetiae in experimental pulmonary mucormycosis: Correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. Medical Mycol (in press).
9. O'Connell MA, Pluss JL, Schkade P, et al. Rhizopus-induced hypersensitivity pneumonitis in a tractor driver. J Allergy Clin Immunol. 1995;95:779-80.
10. Spellberg B, Edwards Jr. J, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69. (Pubitemid 40995116)
11. Levitz SM, Selsted ME, Ganz T, et al. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986;154:483-9. (Pubitemid 16020123)
12. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against Zygomycetes. Clin Infect Dis. 2012;54 Suppl 1:S61-6. Comprehensive review of innate host defenses against mucorales.
13. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun. 1982;38:487-95. (Pubitemid 12002663)
14. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis. 1984;150:752-60. (Pubitemid 15200085)
15. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucomycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74:150-60. (Pubitemid 14086055)
16. Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621-7.
17. Bagdade JD. Phagocytic and microbicidal function in diabetes mellitus. Acta Endocrinol Suppl (Copenh). 1976;205:27-34.
18. Bybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1-13.
19. Baldwin DA, De Sousa DM, Von Wandruszka RM. The effect of pH on the kinetics of iron release from human transferrin. Biochim Biophys Acta. 1982;719:140-6. (Pubitemid 13223078)
20. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: Transferrin and iron availability. Diabetes. 1982;31:1109-14. (Pubitemid 13242245)
21. Espinoza CG, Halkias DG. Pulmonary mucormycosis as a complication of chronic salicylate poisoning. Am J Clin Pathol. 1983;80:508-11. (Pubitemid 13022732)
22. Lewis LL, Hawkins HK, Edwards MS. Disseminated mucormycosis in an infant with methylmalonicaciduria. Pediatr Infect Dis J. 1990;9:851-4. (Pubitemid 20385456)
23. Ibrahim A, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54:S16-22.
24. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843-50. (Pubitemid 24172854)
25. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18:660-7.
26. Boelaert JR, van Roost GF, Vergauwe PL, et al. The role of desferrioxamine in dialysis-Associated mucomycosis: report of three cases and review of the literature. Clin Nephrol. 1988;29:261-6.
27. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307-12. (Pubitemid 29377872)
28. Boelaert JR, de LochtM, Van CutsemJ, et al.Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979-86. (Pubitemid 23141469)
29. Ibrahim AS, Spellberg B, Avanessian V, et al. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73:778-83. (Pubitemid 40165733)
30. Chamilos G, Russell LE, Jianhua H, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A. 2008;105:9367-72.
31. van de Veerdonk FL, Kullberg BJ, van der Meer JW, et al. Hostmicrobe interactions: Innate pattern recognition of fungal pathogens. Curr Opin Microbiol. 2008;11:305-12.
32. Chamilos G, Lewis RE, Lamaris G, et al. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother. 2008;52:722-4. (Pubitemid 351170850)
33. Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infect. 2006;12:404-9.
34. Warris A, Netea MG, Verweij PE, et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. Med Mycol. 2005;43:613-21. (Pubitemid 43084518)
35. Cortez KJ, Lyman CA, Lempicki R, et al. Comparative functional genomics of innate host defense molecules in human monocytes infected with Aspergillus fumigatus and Rhizopus Oryzae (abstr M-1773/393). In 46th Interscience Conference Antimicrob. Agents Chemother. San Francisco CA; 2006.
36. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferongamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes againstmedically important zygomycetes. J Infect Dis. 2005;191:1180-7. (Pubitemid 40404378)
37. Simitsopoulou M, Georgiadou E, Walsh TJ, Roilides E. Cunninghamella bertholetiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. Med Mycol. 2010;48:720-4.
38. Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: Results of population-based laboratory active surveillance. Clin Infect Dis. 1998;27:1138-47.
39. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: A hypothesis. Clin Infect Dis. 2007;44:1089-90. (Pubitemid 46580278)
40. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Mucormycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851-6. (Pubitemid 32250321)
41. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-17. (Pubitemid 34229758)
42. Lewis RE, Liao G, Wang W, et al. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348-55. Valuable study of mechanisms of voriconazole in selecting for Rhizopus oryzae.
43. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743-6. (Pubitemid 39180450)
44. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Mucormycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-Active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-60.
45. Marty FM, Cosimi LA, Baden LR. Breakthrough mucormycosis after voriconazole treatment in recipients of hematopoietic stemcell transplants. N Engl J Med. 2004;350:950-2. (Pubitemid 38252550)
46. Oren H. Breakthrough mucormycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005;40:770-1.
47. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive mucormycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584-7. (Pubitemid 39120940)
48. Vigouroux S, Morin O, Moreau P, et al. Mucormycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: Attention required. Clin Infect Dis. 2005;40:E35-7.
49. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, doubleblind trial of fluconazole vs. voriconazole for the prevention of invasive fungal disease after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111-8.
50. Diwakar A, Dewan RK, Chowdhary A, Randhawa HS, Khanna G, Gaur SN. Mucormycosis-A case report and overview of the disease in India. Mycoses. 2007;50:247-54. (Pubitemid 46920279)
51. Anaissie EJ, Shikhani AH. Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature. Laryngoscope. 1985;95:1107-13. (Pubitemid 15227692)
52. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: Evolution of the disease and treatment options. Laryngoscope. 1997;107:855-62. (Pubitemid 27284306)
53. Varghese A, Thomas S. Orbital apex syndrome secondary to mucormycosis after a tooth extraction in an immunocompetent patient. Ear Nose Throat J. 2010;89:E24-6.
54. Feeley MA, Righi PD, Davis TE, Greist A. Mucormycosis of the paranasal sinuses and septum. Otolaryngol Head Neck Surg. 1999;120:750. (Pubitemid 29226268)
55. Humphry RC, Wright G, Rich WJ, Simpson R. Acute proptosis and blindness in a patient with orbital phycomycosis. J R Soc Med. 1989;82:304-5. (Pubitemid 19123572)
56. Parthiban K, Gnanaguruvelan S, Janaki C, et al. Rhinocerebral mucormycosis. Mycoses. 1998;41:51-3.
57. Anand VK, Alemar G, Griswold Jr. JA. Intracranial complications of mucormycosis: An experimental model and clinical review. Laryngoscope. 1992;102:656-62.
58. Gokcil Z, Odabasi Z, Kutukcu Y, et al. Rhino-orbito-cerebral mucormycosis. J Neurol. 1998;245:689-90.
59. Smith JL, Stevens DA. Survival in cerebro-rhino-orbital mucormycosis and cavernous sinus thrombosis with combined therapy. South Med J. 1986;79:501-4.
60. Galetta SL, Wulc AE, Goldberg HI, et al. Rhinocerebral mucormycosis: Management and survival after carotid occlusion. Ann Neurol. 1990;28:103-7. (Pubitemid 20222162)
61. Chawla B, Sharma S, Kashyap S, Kabra SK, Pushker N, Bajaj MS. Primary orbital mycosis in immunocompetent infants. J AAPOS. 2011;15:211-3.
62. Mbarek C, Zribi S, Khamassi K, Hariga I, Ouni H, Ben Amor M, Ben Gamra O, El Khedim A. Rhinocerebral mucormycosis: Five cases and a literature review. B-ENT. 2011;7:189-93.
63. Ketenci I, Unlü Y, Kaya H, Somdaş MA, Kontaş O, Oztürk M, Vural A. Rhinocerebral mucormycosis: Experience in 14 patients. J Laryngol Otol. 2011;125:e3.
64. Lazo A, Wilner HI, Metes JJ. Craniofacial mucormycosis: Computed tomographic and angiographic findings in two cases. Radiology. 1981;139:623-6. (Pubitemid 11072787)
65. Greenberg MR, Lippman SM, Grinnell VS, Colman MF, Edwards Jr. JE. Computed tomographic findings in orbital Mucor. West J Med. 1985;143:102-3. (Pubitemid 15249036)
66. Press GA, Weindling SM, Hesselink JR, Ochi JW, Harris JP. Rhinocerebral mucormycosis: MR manifestations. J Comput Assist Tomogr. 1988;12:744-9.
67. Deshazo RD. Syndromes of invasive fungal sinusitis. Med Mycol. 2009;47:S309-14.
68. Yeh S, Foroozan R. Orbital apex syndrome. Curr Opin Ophthalmol. 2004;15:490-8. (Pubitemid 39564470)
69. René C. Update on orbital anatomy. Eye. 2006;20:1119-29. (Pubitemid 44515573)
70. Karakurum B, Karatas M, Cagici AC, et al. Mucormycosis presenting with painful ophthalmoplegia. Acta Neurol Belg. 2005;105:201-5. (Pubitemid 43173721)
71. Balch K, Phillips PH, Newman NJ. Painless orbital apex syndrome from mucormycosis. J Neuroophthalmol. 1997;17:178-82. (Pubitemid 27387756)
72. Walsh TJ, GamaletsouMN,McGinnisMR, Hayden R, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54 Suppl 1:S55-60.
73. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with Hematologic malignancy who have mucormycosis. Clin Infect Dis. 2008;47:503-9.
74. Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med. 1984;108:616-8. (Pubitemid 14098798)
75. McDermott NE, Barrett J, Hipp J, et al. Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109: E64-9.
76. Kasai M, Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary mucormycosis. J Clin Microbiol. 2008;46:3690-702.
77. Blitzer A, LawsonW, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980;90:635-48. (Pubitemid 10131495)
78. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39:3-22. (Pubitemid 24243492)
79. Antachopoulos C, Meletiadis J, Roilides E, et al. Rapid susceptibility testing of medically important zygomycetes by XTTassay. J Clin Microbiol. 2006;44:553-60. (Pubitemid 43222251)
80. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39:954-8. (Pubitemid 32209706)
81. Odds FC, van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998;42:282-8. (Pubitemid 28114432)
82. Otcenasek M, Buchta V. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens. Mycopathologia. 1994;128:135-7.
83. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30:251-5. (Pubitemid 28210124)
84. Van Cutsem J, Van Gerven F, Fransen J, Janssen PA. Treatment of experimental mucormycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy. 1989;35:267-72. (Pubitemid 19212408)
85. Watson DC, Neame PB. In vitro activity of amphotericin B on strains of Mucoraceae pathogenic to man. J Lab Clin Med. 1960;56:251-7.
86. Spellberg B, Fu Y, Edwards Jr. JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated mucormycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830-2. (Pubitemid 40175710)
87. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52:1556-8. (Pubitemid 351522035)
88. Reed C, Bryant R, Ibrahim AS, et al. Combination polyenecaspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364-71. (Pubitemid 352009357)
89. Dannaoui E, Meletiadis J,Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51:45-52. (Pubitemid 36163826)
90. Dannaoui E, Afeltra J, Meis J, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 2002;46:2708-11. (Pubitemid 34793494)
91. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses. 2005;48:246-50. (Pubitemid 40965943)
92. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581-2. (Pubitemid 34415351)
93. Gaviria JM, Grohskopf LA, Barnes R, Root RK. Successful treatment of rhinocerebral mucormycosis: A combined-strategy approach. Clin Infect Dis. 1999;28:160-1. (Pubitemid 29246156)
94. Gaziev D, Baronciani D, Galimberti M, et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant. 1996;17:409-14.
95. Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of mucormycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45:1351-60. (Pubitemid 38701909)
96. Hunstad DA, Cohen AH, St Geme 3rd JW. Successful eradication of mucormycosis occurring in a pulmonary allograft. J Heart Lung Transplant. 1999;18:801-4. (Pubitemid 29424120)
97. Leleu X, Sendid B, Fruit J, et al. Combined anti-fungal therapy and surgical resection as treatment of pulmonary mucormycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:417-20. (Pubitemid 29403449)
98. Linden P,Williams P, Chan KM. Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant. 2000;14:329-39. (Pubitemid 30497137)
99. Maury S, Leblanc T, Feuihade M, Molina J-M, Schaison G. Successful treatement of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis. 1998;26:200-2. (Pubitemid 28068189)
100. Mazade MA, Margolin JF, Rossmann SN, Edwards MS. Survival from pulmonary infection with Cunninghamella bertholletiae: Case report and review of the literature. Pediatr Infect Dis J. 1998;17:835-9. (Pubitemid 28475557)
101. Meis JF, Kullberg BJ, Pruszczynski M, Veth RP. Severe osteomyelitis due to the zygomycete Apophysomyces elegans. J Clin Microbiol. 1994;32:3078-81. (Pubitemid 24364024)
102. Moses AE, Rahav G, Barenholz Y, et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin Infect Dis. 1998;26:1430-3. (Pubitemid 28270177)
103. Nenoff P, Kellermann S, Schober R, et al. Rhinocerebral mucormycosis following bone marrow transplantation in chronic myelogenous leukaemia. Report of a case and review of the literature. Mycoses. 1998;41:365-72. (Pubitemid 29039388)
104. Okhuysen PC, Rex JH, Kapusta M, Fife C. Successful treatment of extensive posttraumatic soft-Tissue and renal infections due to Apophysomyces elegans. Clin Infect Dis. 1994;19:329-31. (Pubitemid 24258938)
105. Saltoglu N, Tasova Y, Zorludemir S, Dundar IH. Rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Mycoses. 1998;41:45-9. (Pubitemid 28246433)
106. St-Germain G, Robert A, Ishak M, et al. Infection due to Rhizomucor pusillus: report of four cases in patients with leukemia and review. Clin Infect Dis. 1993;16:640-5. (Pubitemid 23136562)
107. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med. 1996;156:337-9. (Pubitemid 26058487)
108. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-96. (Pubitemid 28270170)
109. Shoham S, Magill SS, Merz WG, et al. Primary treatment of mucormycosis with liposomal amphotericin B: Analysis of 28 cases. Med Mycol. 2010;48:511-7.
110. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487-96. (Pubitemid 33107867)
111. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents -pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997-2020. (Pubitemid 39280370)
112. Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressedmouse model. Antimicrob Agents Chemother. 2002;46:2310-2. (Pubitemid 34665939)
113. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623-6. (Pubitemid 36994692)
114. Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: More evidence of the utility of azoles for mucormycosis. Mycoses. 2004;47:159-62. (Pubitemid 38570090)
115. Mathew R, Kumaravel S, Kuruvilla S, et al. Successful treatment of extensive basidiobolomycosis with oral itraconazole in a child. Int J Dermatol. 2005;44:572-5. (Pubitemid 40960119)
116. Quinio D, Karam A, Leroy JP, et al. Mucormycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol. 2004;42:177-80. (Pubitemid 38489027)
117. Dannaoui E, Meis J, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated mucormycosis. Antimicrob Agents Chemother. 2003;47:3647-50. (Pubitemid 37345740)
118. Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786-8.
119. Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono-or combination therapy for treatment of murine mucormycosis. Antimicrob Agents Chemother. 2009;53:772-5.
120. Van Burik JAH, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in mucormycosis: A retrospective summary of 91 cases. Clin Infect Dis. 2006;42:E61-5.
121. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for mucormycosis. Antimicrob Agents Chemother. 2006;50:126-33.
122. Brugiere O, Dauriat G, Mal H, et al. Pulmonary mucormycosis (mucormycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation. 2005;80:544-5. (Pubitemid 41209432)
123. Garbino J, Uckay I, Amini K, et al. Absidia posttraumatic infection: Successful treatment with posaconazole. J Infect. 2005;51: E135-8. (Pubitemid 41554857)
124. Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (Mucormycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36:1488-91. (Pubitemid 36702884)
125. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr. J, Ibrahim AS. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis. 2009;48:1743-51.
126. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649-57. (Pubitemid 47494365)
127. Reed C, Ibrahim A, Edwards Jr. JE, et al. Deferasirox, an ironchelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50:3968-9. (Pubitemid 44684931)
128. Caldwell J. Effects of high partial pressures of oxygen on fungi. Nature. 1963;197:772-4.
129. Karsner HT, Saphir O. Influence of high partial pressures of oxygen on the growth of certain molds. J Infect Dis. 1926;39:231-6.
130. Robb SM. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J Gen Microbiol. 1966;45:17-29.
131. Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-Tissue mucormycosis complicating diabetes mellitus. Plast Reconstr Surg. 1998;102:822-4. (Pubitemid 28402628)
132. Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy.ArchOtolaryngol Head Neck Surg. 1988;114:791-4.
133. De La Paz MA, Patrinely JR, Marines HM, Appling WD. Adjunctive hyperbaric oxygen in the treatment of bilateral cerebro-rhinoorbital mucormycosis. Am J Ophthalmol. 1992;114:208-11.
134. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated mucormycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granuloyte colony-stimulating factor. Clin Infect Dis. 1997;24:192-6. (Pubitemid 27081542)
135. Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: An 11-year experience. Haematologica. 2009;94:1661-8.
136. Liles WC, Huang JE, van Burik J-AH, et al. Granulocyte colonystimulating factor administered in vivo augments neutrophilmediated activity against opportunistic fungal pathogens. J Infect Dis. 1997;175:1012-5. (Pubitemid 27142990)
137. Mayer P, Schutze E, Lam C, et al. Recombinant murine granulocyte- macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis. 1991;163:584-90.
138. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:11-23. (Pubitemid 38084128)
139. Pursell K, Verral S, Daraiesh F, et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: In vitro effect of r-metHuG-CSF (Filgrastim). Transpl Infect Dis. 2003;5:29-37. (Pubitemid 36705902)
140. Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583-96. (Pubitemid 40825819)
141. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl JMed. 1988;318:869-76. (Pubitemid 18092476)
142. Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer. 1990;66:1904-9. (Pubitemid 20385958)
143. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769-73. (Pubitemid 39063294)
144. Sahin B, Paydas S, Cosar E, et al. Role of granulocyte colonystimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis. 1996;15:866-9. (Pubitemid 26421620)
145. Bhatia S, McCullough J, Perry EH, et al. Granulocyte transfusion: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion. 1994;34:226-32. (Pubitemid 24109648)
146. Hester JP, Dignani MC, Anaissie EJ, et al. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher. 1995;10:188-93. (Pubitemid 26019984)
147. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colonystimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia. 1997;11:1621-30. (Pubitemid 27458598)
148. Jendiroba DB, Lichtiger B, Anaissie E, et al. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion. 1998;38:722-8. (Pubitemid 28381740)
149. Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion: revisited. Curr Hematol Rep. 2003;2:522-7.
150. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia-new drugs and immunotherapy. Best Pract Res Clin Haematol. 2008;21:683-90.
151. Langford JD, McCartney DL, Wang RC. Frozen section-guided surgical debridement for management of rhino-orbital mucormycosis. Am J Ophthalmol. 1997;124:265-7. (Pubitemid 27335313)
152. Abedi E, Sismanis A, Choi K, Pastore P. Twenty-five years' experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope. 1984;94:1060-2. (Pubitemid 14060568)
153. Gupta AK, Mann SB, Khosla VK, et al. Non-randomized comparison of surgical modalities for paranasal sinus mycoses with intracranial extension. Mycoses. 1999;42:225-30. (Pubitemid 29332092)
154. Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhino-orbital mucormycosis without exenteration: The use of multiple treatment modalities. Ophthal Plast Reconstr Surg. 2001;17:62-6. (Pubitemid 32096614)